论文部分内容阅读
目的观察华法令预防脑梗死复发的疗效及安全性。方法选择2001-03～2004-05广东潮州市中心医院168例缺血性脑卒中,随机分成2组,华法令治疗组和抵克立得对照组。华法令组82例,应用华法令0.75～2.25mg/d,口服并监测凝血酶原时间(PT)和国际标准比值(INR),使INR在1.5～2.0之间;抵克立得组86例,口服抵克立得250mg/d。2组分别每月随诊1次,共随诊3年,记录复发情况及药物不良反应。结果华法令组复发8例,复发率9.76%,抵克立得组复发26例,复发率30.02%,两组比较差异有显著性意义(P<0.01)华法令组皮肤紫癜2例,牙龈出血3例,不良反应发生率6.1%;而抵克立得组胃肠不适12例,皮疹6例,皮下淤血3例,粒细胞减少1例,不良反应发生率25.6%。2组不良反应发生率差异有显著性意义(P<0.05)。结论小剂量华法令在缺血性脑卒中二级预防中降低复发率,疗效肯定,比较安全,且价格便宜,可供临床选择应用。
Objective To observe the efficacy and safety of warfarin in preventing recurrent cerebral infarction. Methods Sixty-eight patients with ischemic stroke in Chaozhou Central Hospital of Guangdong Province from 2001-03 to 2004-05 were randomly divided into two groups: warfarin treatment group and nifedipine control group. Warfarin group 82 cases, the application of warfarin 0.75 ~ 2.25mg / d, oral and monitoring of prothrombin time (PT) and the international standard ratio (INR), INR in 1.5 to 2.0; , Orally arrived at the legislature 250mg / d. Two groups were followed up once a month, a total of 3 years follow-up, record the recurrence and adverse drug reactions. Results The recurrence rate was 9.76% in warfarin group and 26 in rocetrel group, with a recurrence rate of 30.02%. There was significant difference between the two groups (P <0.01). 2 cases of skin purpura in warfarin group, gingival bleeding The incidence of adverse reactions was 6.1%. However, 12 cases of gastrointestinal discomfort, 6 cases of skin rashes, 3 cases of subcutaneous congestion, 1 case of neutropenia and 25.6% of adverse reactions were found in the group receiving levofloxacin. The incidence of adverse reactions in the two groups was significantly different (P <0.05). Conclusion Low-dose warfarin can reduce the relapse rate in secondary prevention of ischemic stroke. The curative effect is definite, safe and cheap, which can be used clinically for selection.